COVID-19-associated cardiogenic shock: Difference between revisions
No edit summary |
Nick Menzel (talk | contribs) No edit summary |
||
Line 9: | Line 9: | ||
{{SK}}: Novel coronavirus, COVID-19, Wuhan coronavirus, coronavirus disease-19, coronavirus disease 2019, SARS-CoV-2, COVID-19, 2019-nCoV, 2019 novel coronavirus, cardiovascular finding in COVID-19, cardiogenic shock, COVID-19 associated cardiogenic shock | {{SK}}: Novel coronavirus, COVID-19, Wuhan coronavirus, coronavirus disease-19, coronavirus disease 2019, SARS-CoV-2, COVID-19, 2019-nCoV, 2019 novel coronavirus, cardiovascular finding in COVID-19, cardiogenic shock, COVID-19 associated cardiogenic shock | ||
==Overview== | ==Overview== | ||
The first confirmed instance of [[cardiogenic shock]] due to [[COVID-19]] infection through [[myocardial]] infection by viral particles was in a 69-year-old patient from Italy. This was confirmed via [[biopsy]]. Since then, the two most probable mechanisms of [[cardiogenic shock]] related to [[Covid-19|COVID-19]] are direct invasion and [[cytokine storm]]. According to a recent study out of an ICU in Washington state, one-third of critically ill patients with COVID-19 had clinical signs of [[cardiogenic shock]] and [[cardiomyopathy]]. According to another observational study in China, [[COVID-19]] associated [[cardiogenic shock]] has a poor prognosis. | |||
==Historical Perspective== | ==Historical Perspective== | ||
* | *The [[novel coronavirus]], [[SARS-CoV-2]], is identified as the cause of an outbreak of [[respiratory illness]] first detected in Wuhan, China in late December 2019. It was named [[SARS-CoV-2]] for its similarity [[severe acute respiratory syndrome]] related [[coronaviruses]] such as [[SARS-CoV]], which caused [[acute respiratory distress syndrome]] ([[ARDS]]) in 2002–2003. <ref>{{Cite web|url=https://www.cdc.gov/coronavirus/2019-ncov/about/index.html|title=|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref><ref name="LuCui2020">{{cite journal|last1=Lu|first1=Jian|last2=Cui|first2=Jie|last3=Qian|first3=Zhaohui|last4=Wang|first4=Yirong|last5=Zhang|first5=Hong|last6=Duan|first6=Yuange|last7=Wu|first7=Xinkai|last8=Yao|first8=Xinmin|last9=Song|first9=Yuhe|last10=Li|first10=Xiang|last11=Wu|first11=Changcheng|last12=Tang|first12=Xiaolu|title=On the origin and continuing evolution of SARS-CoV-2|journal=National Science Review|year=2020|issn=2095-5138|doi=10.1093/nsr/nwaa036}}</ref> | ||
*On March 12, 2020, the WHO declared | *On March 12, 2020, the WHO declared the Coronavirus disease 2019 (COVID-19) outbreak to be a pandemic.<ref name="urlCoronavirus (COVID-19) events as they happen">{{cite web |url=https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen |title=Coronavirus (COVID-19) events as they happen |format= |work= |accessdate=}}</ref> | ||
* | *The first confirmed instance of [[cardiogenic shock]] due to [[COVID-19]] infection through [[myocardial]] infection by viral particles was in a 69-year-old patient from Italy. This was confirmed via [[biopsy]]. <ref name="TavazziPellegrini2020">{{cite journal|last1=Tavazzi|first1=Guido|last2=Pellegrini|first2=Carlo|last3=Maurelli|first3=Marco|last4=Belliato|first4=Mirko|last5=Sciutti|first5=Fabio|last6=Bottazzi|first6=Andrea|last7=Sepe|first7=Paola Alessandra|last8=Resasco|first8=Tullia|last9=Camporotondo|first9=Rita|last10=Bruno|first10=Raffaele|last11=Baldanti|first11=Fausto|last12=Paolucci|first12=Stefania|last13=Pelenghi|first13=Stefano|last14=Iotti|first14=Giorgio Antonio|last15=Mojoli|first15=Francesco|last16=Arbustini|first16=Eloisa|title=Myocardial localization of coronavirus in COVID‐19 cardiogenic shock|journal=European Journal of Heart Failure|volume=22|issue=5|year=2020|pages=911–915|issn=1388-9842|doi=10.1002/ejhf.1828}}</ref> | ||
To view the historical perspective of COVID-19, [[COVID-19 historical perspective|click here]]. | |||
==Classification== | ==Classification== | ||
Line 22: | Line 24: | ||
==Pathophysiology== | ==Pathophysiology== | ||
The two most likely mechanisms that contribute to [[Covid-19|COVID-19]] [[cardiogenic shock]] are: <ref name="SiddiqiMehra2020">{{cite journal|last1=Siddiqi|first1=Hasan K.|last2=Mehra|first2=Mandeep R.|title=COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal|journal=The Journal of Heart and Lung Transplantation|volume=39|issue=5|year=2020|pages=405–407|issn=10532498|doi=10.1016/j.healun.2020.03.012}}</ref> <ref name="YeWang2020">{{cite journal|last1=Ye|first1=Qing|last2=Wang|first2=Bili|last3=Mao|first3=Jianhua|title=The pathogenesis and treatment of the `Cytokine Storm' in COVID-19|journal=Journal of Infection|volume=80|issue=6|year=2020|pages=607–613|issn=01634453|doi=10.1016/j.jinf.2020.03.037}}</ref> | |||
* Direct invasion of the virus into the [[cardiomyocytes]] | * Direct invasion of the virus into the [[cardiomyocytes]] | ||
* [[Cytokine storm]] activated by [[T helper cells]] ([[Th1]] and [[Th2]]) | * [[Cytokine storm]] activated by [[T helper cells]] ([[Th1]] and [[Th2]]) that triggers a systemic hyperinflammatory response | ||
==Causes== | ==Causes== | ||
The causes of [[cardiogenic shock]] related to [[COVID-19]] | The causes of [[cardiogenic shock]] related to [[COVID-19]] may include: <ref name="MahajanChandra2020">{{cite journal|last1=Mahajan|first1=Kunal|last2=Chandra|first2=K.Sarat|title=Cardiovascular comorbidities and complications associated with coronavirus disease 2019|journal=Medical Journal Armed Forces India|year=2020|issn=03771237|doi=10.1016/j.mjafi.2020.05.004}}</ref> <ref name="BelhadjerMéot2020">{{cite journal|last1=Belhadjer|first1=Zahra|last2=Méot|first2=Mathilde|last3=Bajolle|first3=Fanny|last4=Khraiche|first4=Diala|last5=Legendre|first5=Antoine|last6=Abakka|first6=Samya|last7=Auriau|first7=Johanne|last8=Grimaud|first8=Marion|last9=Oualha|first9=Mehdi|last10=Beghetti|first10=Maurice|last11=Wacker|first11=Julie|last12=Ovaert|first12=Caroline|last13=Hascoet|first13=Sebastien|last14=Selegny|first14=Maëlle|last15=Malekzadeh-Milani|first15=Sophie|last16=Maltret|first16=Alice|last17=Bosser|first17=Gilles|last18=Giroux|first18=Nathan|last19=Bonnemains|first19=Laurent|last20=Bordet|first20=Jeanne|last21=Di Filippo|first21=Sylvie|last22=Mauran|first22=Pierre|last23=Falcon-Eicher|first23=Sylvie|last24=Thambo|first24=Jean-Benoît|last25=Lefort|first25=Bruno|last26=Moceri|first26=Pamela|last27=Houyel|first27=Lucile|last28=Renolleau|first28=Sylvain|last29=Bonnet|first29=Damien|title=Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic|journal=Circulation|year=2020|issn=0009-7322|doi=10.1161/CIRCULATIONAHA.120.048360}}</ref> | ||
* Newly emerging COVID-19 associated [[myocarditis]], [[cardiac arrhythmias]], [[cardiomyopathy]], or an [[acute coronary syndrome]] deteriorated into [[cardiogenic shock]] | * Newly emerging COVID-19 associated [[myocarditis]], [[cardiac arrhythmias]], [[cardiomyopathy]], or an [[acute coronary syndrome]] deteriorated into [[cardiogenic shock]] | ||
Line 74: | Line 76: | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
*According to a recent study, one-third of critically ill patients with COVID-19 | *According to a recent study out of an ICU in Washington state, one-third of critically ill patients with COVID-19 had clinical signs of [[cardiogenic shock]] and [[cardiomyopathy]].<ref name="pmid32191259">{{cite journal| author=Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M | display-authors=etal| title=Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. | journal=JAMA | year= 2020 | volume= | issue= | pages= | pmid=32191259 | doi=10.1001/jama.2020.4326 | pmc=7082763 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32191259 }} </ref> There are few anecdotal reports of [[cardiogenic shock]] related to [[COVID-19]]. <ref name="TavazziPellegrini2020">{{cite journal|last1=Tavazzi|first1=Guido|last2=Pellegrini|first2=Carlo|last3=Maurelli|first3=Marco|last4=Belliato|first4=Mirko|last5=Sciutti|first5=Fabio|last6=Bottazzi|first6=Andrea|last7=Sepe|first7=Paola Alessandra|last8=Resasco|first8=Tullia|last9=Camporotondo|first9=Rita|last10=Bruno|first10=Raffaele|last11=Baldanti|first11=Fausto|last12=Paolucci|first12=Stefania|last13=Pelenghi|first13=Stefano|last14=Iotti|first14=Giorgio Antonio|last15=Mojoli|first15=Francesco|last16=Arbustini|first16=Eloisa|title=Myocardial localization of coronavirus in COVID‐19 cardiogenic shock|journal=European Journal of Heart Failure|volume=22|issue=5|year=2020|pages=911–915|issn=1388-9842|doi=10.1002/ejhf.1828}}</ref> <ref name="Sánchez-RecaldeSolano-López2020">{{cite journal|last1=Sánchez-Recalde|first1=Ángel|last2=Solano-López|first2=Jorge|last3=Miguelena-Hycka|first3=Javier|last4=Martín-Pinacho|first4=Jesús Javier|last5=Sanmartín|first5=Marcelo|last6=Zamorano|first6=José L.|title=COVID-19 and cardiogenic shock. Different cardiovascular presentations with high mortality|journal=Revista Española de Cardiología (English Edition)|year=2020|issn=18855857|doi=10.1016/j.rec.2020.04.012}}</ref> | ||
===Age=== | ===Age=== | ||
Line 103: | Line 105: | ||
===Diagnostic Study of Choice=== | ===Diagnostic Study of Choice=== | ||
* | * A diagnosis of [[cardiogenic shock]] related to [[COVID-19]] can be made when Systolic [[Blood Pressure]] is lower than 90 mmHg for more than 15 minutes with impaired organ perfusion while [[Urine output]] is less than 30 m/hr in a patient with [[COVID-19]] disease.<ref name="DhakalSweitzer2020">{{cite journal|last1=Dhakal|first1=Bishnu P.|last2=Sweitzer|first2=Nancy K.|last3=Indik|first3=Julia H.|last4=Acharya|first4=Deepak|last5=William|first5=Preethi|title=SARS-CoV-2 Infection and Cardiovascular Disease: COVID-19 Heart|journal=Heart, Lung and Circulation|year=2020|issn=14439506|doi=10.1016/j.hlc.2020.05.101}}</ref> | ||
To view cardiogenic shock diagnostic criteria, [[cardiogenic shock diagnostic criteria|click here]]. | |||
===History and Symptoms:=== | ===History and Symptoms:=== | ||
* | * According to anecdotal reports, some patients that have presented with [[COVID-19]] related [[cardiogenic shock]] did not have any [[cardiovascular]] risk factors. | ||
* A 69-year-old patient from Italy has been reported by Tavazzi et al., as a | * A 69-year-old patient from Italy has been reported by Tavazzi et al., as a COVID-19-associated cardiogenic shock case. | ||
* | ** This patient had flu-like symptoms when hospitalized and quickly deteriorated into [[respiratory distress]] and [[cardiogenic shock]]. <ref name="TavazziPellegrini2020">{{cite journal|last1=Tavazzi|first1=Guido|last2=Pellegrini|first2=Carlo|last3=Maurelli|first3=Marco|last4=Belliato|first4=Mirko|last5=Sciutti|first5=Fabio|last6=Bottazzi|first6=Andrea|last7=Sepe|first7=Paola Alessandra|last8=Resasco|first8=Tullia|last9=Camporotondo|first9=Rita|last10=Bruno|first10=Raffaele|last11=Baldanti|first11=Fausto|last12=Paolucci|first12=Stefania|last13=Pelenghi|first13=Stefano|last14=Iotti|first14=Giorgio Antonio|last15=Mojoli|first15=Francesco|last16=Arbustini|first16=Eloisa|title=Myocardial localization of coronavirus in COVID‐19 cardiogenic shock|journal=European Journal of Heart Failure|volume=22|issue=5|year=2020|pages=911–915|issn=1388-9842|doi=10.1002/ejhf.1828}}</ref> | ||
* Four patients with [[cardiogenic shock]] complication related to [[COVID-19]] were reported by Sanchez-Recalde, et al. | * Four patients with [[cardiogenic shock]] complication related to [[COVID-19]] were reported by Sanchez-Recalde, et al. | ||
* | ** These patients were hospitalized between March 1, 2020 and April 15, 2020 and included:<ref name="Sánchez-RecaldeSolano-López2020">{{cite journal|last1=Sánchez-Recalde|first1=Ángel|last2=Solano-López|first2=Jorge|last3=Miguelena-Hycka|first3=Javier|last4=Martín-Pinacho|first4=Jesús Javier|last5=Sanmartín|first5=Marcelo|last6=Zamorano|first6=José L.|title=COVID-19 and cardiogenic shock. Different cardiovascular presentations with high mortality|journal=Revista Española de Cardiología (English Edition)|year=2020|issn=18855857|doi=10.1016/j.rec.2020.04.012}}</ref> | ||
***A 42-year-old woman, who had [[dyslipidemia]] as a [[cardiovascular]] risk factor | |||
* A 42-year-old woman, who had [[dyslipidemia]] as a [[cardiovascular]] risk factor | ***A 50-year-old man, without any [[cardiovascular]] risk factors, admitted with severe bilateral [[pneumonia]] related to COVID-19. After a few hours, he developed [[cardiogenic shock]] | ||
* A 50-year-old man, without any [[cardiovascular]] risk factors, admitted | ***A 75-year-old man who did not have any [[cardiovascular]] risk factors and was admitted due to [[dyspnea]], [[chest pain]], and bilateral [[COVID-19]] [[pneumonia]] | ||
* A 75-year-old man did not have any [[cardiovascular]] risk factors and was admitted due to [[dyspnea]], [[chest pain]], and bilateral [[ | ***A 37-year-old woman, with a history of obesity and [[deep venous thrombosis]], and had symptoms of [[dyspnea]] and chest pain | ||
* A 37-year-old woman, | |||
=== Physical Examination === | === Physical Examination === | ||
Physical examination may be | Physical examination findings that may be of note for the diagnosis of [[Covid-19 associated cardiogenic shock]] include:<ref>{{cite book | last = Tse | first = FirstName | title = Oxford Desk Reference : Cardiology | publisher = OUP Oxford | location = Oxford | year = 2011 | isbn = 978-0-19-956809-3 }} </ref> | ||
:*Assessment of consciousness level | :*Assessment of consciousness level | ||
:*Extremities, whether they are warm or cool, is helpful for evaluation of [[cardiogenic shock]] | :*Extremities, whether they are warm or cool, is helpful for evaluation of [[cardiogenic shock]] | ||
Line 131: | Line 134: | ||
=== Laboratory Findings === | === Laboratory Findings === | ||
*In [[COVID-19]] patients, it is essential to differentiate the shock | *In [[COVID-19]] patients, it is essential to differentiate the type of shock. Two tests are best able to clarify this, and result in higher levels in patients with [[cardiogenic shock]] related to [[COVID-19]]. These tests are: <ref name="LalHayward2020">{{cite journal|last1=Lal|first1=Sean|last2=Hayward|first2=Christopher S.|last3=De Pasquale|first3=Carmine|last4=Kaye|first4=David|last5=Javorsky|first5=George|last6=Bergin|first6=Peter|last7=Atherton|first7=John J.|last8=Ilton|first8=Marcus K.|last9=Weintraub|first9=Robert G.|last10=Nair|first10=Priya|last11=Rudas|first11=Mate|last12=Dembo|first12=Lawrence|last13=Doughty|first13=Robert N.|last14=Kumarasinghe|first14=Gayathri|last15=Juergens|first15=Craig|last16=Bannon|first16=Paul G.|last17=Bart|first17=Nicole K.|last18=Chow|first18=Clara K.|last19=Lattimore|first19=Jo-Dee|last20=Kritharides|first20=Leonard|last21=Totaro|first21=Richard|last22=Macdonald|first22=Peter S.|title=COVID-19 and Acute Heart Failure: Screening the Critically Ill – A Position Statement of the Cardiac Society of Australia and New Zealand (CSANZ)|journal=Heart, Lung and Circulation|year=2020|issn=14439506|doi=10.1016/j.hlc.2020.04.005}}</ref> | ||
**serum [[brain natriuretic peptide]] ([[BNP]]) | **serum [[brain natriuretic peptide]] ([[BNP]]) | ||
**[[Troponin]] | **[[Troponin]] | ||
* | *In addition, the increase of some biomarkers demonstrates poor prognosis, increased mortality, and more severe symptoms in [[COVID-19]] patients:<ref name="AboughdirKirwin2020">{{cite journal|last1=Aboughdir|first1=Maryam|last2=Kirwin|first2=Thomas|last3=Abdul Khader|first3=Ashiq|last4=Wang|first4=Brian|title=Prognostic Value of Cardiovascular Biomarkers in COVID-19: A Review|journal=Viruses|volume=12|issue=5|year=2020|pages=527|issn=1999-4915|doi=10.3390/v12050527}}</ref> | ||
**[[cTnT]] and [[cTnI]] levels | **[[cTnT]] and [[cTnI]] levels | ||
**The association of elevated [[CK-MB]] and [[BNP]] | **The association of elevated [[CK-MB]] and [[BNP]] | ||
Line 145: | Line 148: | ||
=== X-ray === | === X-ray === | ||
*In a patient with [[COVID-19]]-associated [[cardiogenic shock]], [[CXR]] could manifest coexisting acute respiratory illness and also cardiogenic [[pulmonary edema]]. | *In a patient with [[COVID-19]]-associated [[cardiogenic shock]], [[CXR]] could manifest coexisting acute respiratory illness and also cardiogenic [[pulmonary edema]]. Some findings, such as [[cardiomegaly]] and increased vascular markings, can suggest preexisting [[heart failure]]. <ref name="DrigginMadhavan2020">{{cite journal|last1=Driggin|first1=Elissa|last2=Madhavan|first2=Mahesh V.|last3=Bikdeli|first3=Behnood|last4=Chuich|first4=Taylor|last5=Laracy|first5=Justin|last6=Biondi-Zoccai|first6=Giuseppe|last7=Brown|first7=Tyler S.|last8=Der Nigoghossian|first8=Caroline|last9=Zidar|first9=David A.|last10=Haythe|first10=Jennifer|last11=Brodie|first11=Daniel|last12=Beckman|first12=Joshua A.|last13=Kirtane|first13=Ajay J.|last14=Stone|first14=Gregg W.|last15=Krumholz|first15=Harlan M.|last16=Parikh|first16=Sahil A.|title=Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic|journal=Journal of the American College of Cardiology|volume=75|issue=18|year=2020|pages=2352–2371|issn=07351097|doi=10.1016/j.jacc.2020.03.031}}</ref> | ||
===Echocardiography or Ultrasound=== | ===Echocardiography or Ultrasound=== | ||
*[[Echocardiography]] is an appropriate way | *[[Echocardiography]] is an appropriate way to identify the extent of cardiac involvement in [[COVID-19]]-associated [[cardiogenic shock]] cases.<ref name="LalHayward2020">{{cite journal|last1=Lal|first1=Sean|last2=Hayward|first2=Christopher S.|last3=De Pasquale|first3=Carmine|last4=Kaye|first4=David|last5=Javorsky|first5=George|last6=Bergin|first6=Peter|last7=Atherton|first7=John J.|last8=Ilton|first8=Marcus K.|last9=Weintraub|first9=Robert G.|last10=Nair|first10=Priya|last11=Rudas|first11=Mate|last12=Dembo|first12=Lawrence|last13=Doughty|first13=Robert N.|last14=Kumarasinghe|first14=Gayathri|last15=Juergens|first15=Craig|last16=Bannon|first16=Paul G.|last17=Bart|first17=Nicole K.|last18=Chow|first18=Clara K.|last19=Lattimore|first19=Jo-Dee|last20=Kritharides|first20=Leonard|last21=Totaro|first21=Richard|last22=Macdonald|first22=Peter S.|title=COVID-19 and Acute Heart Failure: Screening the Critically Ill – A Position Statement of the Cardiac Society of Australia and New Zealand (CSANZ)|journal=Heart, Lung and Circulation|year=2020|issn=14439506|doi=10.1016/j.hlc.2020.04.005}}</ref> | ||
===CT scan=== | ===CT scan=== | ||
*Generally, | *Generally, a[[CT scan]] is not suggested as a primary imaging study for evaluating a case of [[cardiogenic shock]] related to [[COVID-19]]. However, it can useful for observing coexisting [[ARDS]] by demonstrating a ground-glass opacity.<ref name="DrigginMadhavan2020">{{cite journal|last1=Driggin|first1=Elissa|last2=Madhavan|first2=Mahesh V.|last3=Bikdeli|first3=Behnood|last4=Chuich|first4=Taylor|last5=Laracy|first5=Justin|last6=Biondi-Zoccai|first6=Giuseppe|last7=Brown|first7=Tyler S.|last8=Der Nigoghossian|first8=Caroline|last9=Zidar|first9=David A.|last10=Haythe|first10=Jennifer|last11=Brodie|first11=Daniel|last12=Beckman|first12=Joshua A.|last13=Kirtane|first13=Ajay J.|last14=Stone|first14=Gregg W.|last15=Krumholz|first15=Harlan M.|last16=Parikh|first16=Sahil A.|title=Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic|journal=Journal of the American College of Cardiology|volume=75|issue=18|year=2020|pages=2352–2371|issn=07351097|doi=10.1016/j.jacc.2020.03.031}}</ref> | ||
To view the CT scan findings on COVID-19, [[COVID-19 CT scan|click here]]. | |||
===MRI=== | ===MRI=== | ||
* | *Generally, in patients with [[COVID-19]]-associated [[cardiogenic shock]], Cardiac [[MRI]] for the assessment of preexisting disorders such as [[myocarditis]] should not be done.<ref name="pmid32601020">{{cite journal| author=Dhakal BP, Sweitzer NK, Indik JH, Acharya D, William P| title=SARS-CoV-2 Infection and Cardiovascular Disease: COVID-19 Heart. | journal=Heart Lung Circ | year= 2020 | volume= | issue= | pages= | pmid=32601020 | doi=10.1016/j.hlc.2020.05.101 | pmc=7274628 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32601020 }} </ref> | ||
To view the MRI findings on COVID-19, [[COVID-19 MRI|click here]].<br /> | |||
===Other Imaging Findings=== | ===Other Imaging Findings=== | ||
Line 170: | Line 177: | ||
* [[Fluid resuscitation]] (crystalloid IV fluids are more efficient than colloid solutions) | * [[Fluid resuscitation]] (crystalloid IV fluids are more efficient than colloid solutions) | ||
* Administration of [[vasopressors]] and [[inotropes]] to stabilize [[shock]] | * Administration of [[vasopressors]] and [[inotropes]] to stabilize [[shock]] | ||
* Assess other types of [[shock]] and mixed etiologies of [[shock]] if hemodynamics not refining, specifically | * Assess other types of [[shock]] and mixed etiologies of [[shock]] if hemodynamics not refining, specifically in patients with a previous [[cardiac abnormality]] <ref name="pmid32601020">{{cite journal| author=Dhakal BP, Sweitzer NK, Indik JH, Acharya D, William P| title=SARS-CoV-2 Infection and Cardiovascular Disease: COVID-19 Heart. | journal=Heart Lung Circ | year= 2020 | volume= | issue= | pages= | pmid=32601020 | doi=10.1016/j.hlc.2020.05.101 | pmc=7274628 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32601020 }} </ref> | ||
===Mechanical Support:=== | ===Mechanical Support:=== | ||
*In treating patients with [[cardiogenic shock]] related to [[COVID-19]], the efficacy of [[extracorporeal membrane oxygenation]] ([[ECMO]]) is indistinct | *In treating patients with [[cardiogenic shock]] related to [[COVID-19]], the efficacy of [[extracorporeal membrane oxygenation]] ([[ECMO]]) is indistinct, however it may be used in the most critically ill and highly selective patients. | ||
*Although specialists implicate [[ECMO]] and mechanical circulatory support devices in severe cased of [[COVID-19]] related [[cardiogenic shock]], the mortality rate if high in those patients who undergo this treatment. | |||
*Although specialists implicate [[ECMO]] and mechanical circulatory support devices in severe | *It has been reported in a case series from China, that most of these patients had a poor prognosis and did not survive despite implicating [[ECMO]]. <ref name="MacLarenFisher2020">{{cite journal|last1=MacLaren|first1=Graeme|last2=Fisher|first2=Dale|last3=Brodie|first3=Daniel|title=Preparing for the Most Critically Ill Patients With COVID-19|journal=JAMA|volume=323|issue=13|year=2020|pages=1245|issn=0098-7484|doi=10.1001/jama.2020.2342}}</ref> <ref name="pmid32105632">{{cite journal| author=Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H | display-authors=etal| title=Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. | journal=Lancet Respir Med | year= 2020 | volume= 8 | issue= 5 | pages= 475-481 | pmid=32105632 | doi=10.1016/S2213-2600(20)30079-5 | pmc=7102538 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32105632 }} </ref> | ||
*It has been reported in a case series from China that most of these patients had a poor prognosis and did not survive despite implicating [[ECMO]]. <ref name="MacLarenFisher2020">{{cite journal|last1=MacLaren|first1=Graeme|last2=Fisher|first2=Dale|last3=Brodie|first3=Daniel|title=Preparing for the Most Critically Ill Patients With COVID-19|journal=JAMA|volume=323|issue=13|year=2020|pages=1245|issn=0098-7484|doi=10.1001/jama.2020.2342}}</ref> <ref name="pmid32105632">{{cite journal| author=Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H | display-authors=etal| title=Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. | journal=Lancet Respir Med | year= 2020 | volume= 8 | issue= 5 | pages= 475-481 | pmid=32105632 | doi=10.1016/S2213-2600(20)30079-5 | pmc=7102538 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32105632 }} </ref> | |||
===Surgery=== | ===Surgery=== | ||
Line 183: | Line 189: | ||
===Primary Prevention === | ===Primary Prevention === | ||
*There are no established measures for the | *There are no established measures for the primary prevention of [[COVID-19]]-associated [[cardiogenic shock]]. | ||
For primary preventive measures of [[COVID-19]], [[COVID-19 primary prevention|click here]]. | |||
===Secondary Prevention=== | ===Secondary Prevention=== | ||
*There are no established measures for the secondary prevention of [[COVID-19]]-associated [[myocarditis]]. | *There are no established measures for the secondary prevention of [[COVID-19]]-associated [[myocarditis]]. | ||
For secondary preventive measures of [COVID-19], [[COVID-19 secondary prevention|click here]]. | |||
==References== | ==References== |
Revision as of 19:36, 23 July 2020
For COVID-19 frequently asked inpatient questions, click here
For COVID-19 frequently asked outpatient questions, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: : Alieh Behjat, M.D.[2]
Synonyms and keywords:: Novel coronavirus, COVID-19, Wuhan coronavirus, coronavirus disease-19, coronavirus disease 2019, SARS-CoV-2, COVID-19, 2019-nCoV, 2019 novel coronavirus, cardiovascular finding in COVID-19, cardiogenic shock, COVID-19 associated cardiogenic shock
Overview
The first confirmed instance of cardiogenic shock due to COVID-19 infection through myocardial infection by viral particles was in a 69-year-old patient from Italy. This was confirmed via biopsy. Since then, the two most probable mechanisms of cardiogenic shock related to COVID-19 are direct invasion and cytokine storm. According to a recent study out of an ICU in Washington state, one-third of critically ill patients with COVID-19 had clinical signs of cardiogenic shock and cardiomyopathy. According to another observational study in China, COVID-19 associated cardiogenic shock has a poor prognosis.
Historical Perspective
- The novel coronavirus, SARS-CoV-2, is identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China in late December 2019. It was named SARS-CoV-2 for its similarity severe acute respiratory syndrome related coronaviruses such as SARS-CoV, which caused acute respiratory distress syndrome (ARDS) in 2002–2003. [1][2]
- On March 12, 2020, the WHO declared the Coronavirus disease 2019 (COVID-19) outbreak to be a pandemic.[3]
- The first confirmed instance of cardiogenic shock due to COVID-19 infection through myocardial infection by viral particles was in a 69-year-old patient from Italy. This was confirmed via biopsy. [4]
To view the historical perspective of COVID-19, click here.
Classification
- There is no specific classification for COVID-19 associated cardiogenic shock. To view cardiogenic shock classification, click here.
Pathophysiology
The two most likely mechanisms that contribute to COVID-19 cardiogenic shock are: [5] [6]
- Direct invasion of the virus into the cardiomyocytes
- Cytokine storm activated by T helper cells (Th1 and Th2) that triggers a systemic hyperinflammatory response
Causes
The causes of cardiogenic shock related to COVID-19 may include: [7] [8]
- Newly emerging COVID-19 associated myocarditis, cardiac arrhythmias, cardiomyopathy, or an acute coronary syndrome deteriorated into cardiogenic shock
- Worsening of previous left ventricular failure due to COVID-19
- COVID-19-associated multisystem inflammatory syndromein children (MIS-C)
Differentiating COVID-19 associated cardiogenic shock from other Diseases
Cardiogenic shock related to COVID-19 must be differentiated from other diseases which include: [9] [10]
- distributive shock
- hypovolemic shock
- mixed (distributive and cardiogenic shock).
Some hemodynamic parameters would help differentiate significant types of shock: [11]
Cardiac Output | Pulmonary Capillary Wedge Pressure | Systemic Vascular Resistance | Pulmonary artery diastolic pressure | SVO2 | |
---|---|---|---|---|---|
COVID-19-associated cardiogenic shock | ↓ | ↑↔ | ↑ | ↑ | ↓ |
Septic shock | ↑ | ↓ | ↓ | ↓ | ↓ |
Hypovolemic shock | ↓ | ↓ | ↑ | ↓ | ↑ |
Epidemiology and Demographics
- According to a recent study out of an ICU in Washington state, one-third of critically ill patients with COVID-19 had clinical signs of cardiogenic shock and cardiomyopathy.[12] There are few anecdotal reports of cardiogenic shock related to COVID-19. [4] [13]
Age
- There is no data on age predilection to cardiogenic shock in COVID-19.
Gender
- There is no data on gender predilection to cardiogenic shock in COVID-19.
Race
- There is no data on racial predilection to cardiogenic shock in COVID-19.
Risk Factors
- There are no established risk factors for COVID-19-associated cardiogenic shock.
- To view risk factors for the severe form of COVID-19 disease, click here.
- Moreover, in order to read more on the risk factors of cardiogenic shock, generally, click here.
Screening
- There is insufficient evidence to recommend routine screening for COVID-19-associated cardiogenic shock.
Natural History, Complications and Prognosis
- According to an observational study in China, COVID-19 associated cardiogenic shock has a poor prognosis.
- In spite of using Extracorporeal membrane oxygenation (ECMO), 83% of patients died. [14] [15]
Diagnosis
Diagnostic Study of Choice
- A diagnosis of cardiogenic shock related to COVID-19 can be made when Systolic Blood Pressure is lower than 90 mmHg for more than 15 minutes with impaired organ perfusion while Urine output is less than 30 m/hr in a patient with COVID-19 disease.[15]
To view cardiogenic shock diagnostic criteria, click here.
History and Symptoms:
- According to anecdotal reports, some patients that have presented with COVID-19 related cardiogenic shock did not have any cardiovascular risk factors.
- A 69-year-old patient from Italy has been reported by Tavazzi et al., as a COVID-19-associated cardiogenic shock case.
- This patient had flu-like symptoms when hospitalized and quickly deteriorated into respiratory distress and cardiogenic shock. [4]
- Four patients with cardiogenic shock complication related to COVID-19 were reported by Sanchez-Recalde, et al.
- These patients were hospitalized between March 1, 2020 and April 15, 2020 and included:[13]
- A 42-year-old woman, who had dyslipidemia as a cardiovascular risk factor
- A 50-year-old man, without any cardiovascular risk factors, admitted with severe bilateral pneumonia related to COVID-19. After a few hours, he developed cardiogenic shock
- A 75-year-old man who did not have any cardiovascular risk factors and was admitted due to dyspnea, chest pain, and bilateral COVID-19 pneumonia
- A 37-year-old woman, with a history of obesity and deep venous thrombosis, and had symptoms of dyspnea and chest pain
- These patients were hospitalized between March 1, 2020 and April 15, 2020 and included:[13]
Physical Examination
Physical examination findings that may be of note for the diagnosis of Covid-19 associated cardiogenic shock include:[16]
- Assessment of consciousness level
- Extremities, whether they are warm or cool, is helpful for evaluation of cardiogenic shock
- Vital signs (tachycardia and hypotension and tachypnea)
- Evaluation of volume status: CVP (increased JVP), edema
- Skin pallor
Laboratory Findings
- In COVID-19 patients, it is essential to differentiate the type of shock. Two tests are best able to clarify this, and result in higher levels in patients with cardiogenic shock related to COVID-19. These tests are: [17]
- serum brain natriuretic peptide (BNP)
- Troponin
- In addition, the increase of some biomarkers demonstrates poor prognosis, increased mortality, and more severe symptoms in COVID-19 patients:[18]
Electrocardiogram
- There is no specific electrocardiographic finding for cardiogenic shock in COVID-19 patients.
- The ECG can help to find previous cardiac abnormalities and triggering factors, such as acute myocardial infarction, and arrhythmias, which could lead to cardiogenic shock [19]
X-ray
- In a patient with COVID-19-associated cardiogenic shock, CXR could manifest coexisting acute respiratory illness and also cardiogenic pulmonary edema. Some findings, such as cardiomegaly and increased vascular markings, can suggest preexisting heart failure. [20]
Echocardiography or Ultrasound
- Echocardiography is an appropriate way to identify the extent of cardiac involvement in COVID-19-associated cardiogenic shock cases.[17]
CT scan
- Generally, aCT scan is not suggested as a primary imaging study for evaluating a case of cardiogenic shock related to COVID-19. However, it can useful for observing coexisting ARDS by demonstrating a ground-glass opacity.[20]
To view the CT scan findings on COVID-19, click here.
MRI
- Generally, in patients with COVID-19-associated cardiogenic shock, Cardiac MRI for the assessment of preexisting disorders such as myocarditis should not be done.[21]
To view the MRI findings on COVID-19, click here.
Other Imaging Findings
- To view other imaging findings on COVID-19, click here.
Other Diagnostic Studies
- To view other diagnostic studies for COVID-19, click here.
Treatment
Cardiogenic shock medical therapy:
- Fluid resuscitation (crystalloid IV fluids are more efficient than colloid solutions)
- Administration of vasopressors and inotropes to stabilize shock
- Assess other types of shock and mixed etiologies of shock if hemodynamics not refining, specifically in patients with a previous cardiac abnormality [21]
Mechanical Support:
- In treating patients with cardiogenic shock related to COVID-19, the efficacy of extracorporeal membrane oxygenation (ECMO) is indistinct, however it may be used in the most critically ill and highly selective patients.
- Although specialists implicate ECMO and mechanical circulatory support devices in severe cased of COVID-19 related cardiogenic shock, the mortality rate if high in those patients who undergo this treatment.
- It has been reported in a case series from China, that most of these patients had a poor prognosis and did not survive despite implicating ECMO. [22] [14]
Surgery
- Surgical intervention is not recommended for the management of COVID-19-associated cardiogenic shock.
Primary Prevention
- There are no established measures for the primary prevention of COVID-19-associated cardiogenic shock.
For primary preventive measures of COVID-19, click here.
Secondary Prevention
- There are no established measures for the secondary prevention of COVID-19-associated myocarditis.
For secondary preventive measures of [COVID-19], click here.
References
- ↑ https://www.cdc.gov/coronavirus/2019-ncov/about/index.html. Missing or empty
|title=
(help) - ↑ Lu, Jian; Cui, Jie; Qian, Zhaohui; Wang, Yirong; Zhang, Hong; Duan, Yuange; Wu, Xinkai; Yao, Xinmin; Song, Yuhe; Li, Xiang; Wu, Changcheng; Tang, Xiaolu (2020). "On the origin and continuing evolution of SARS-CoV-2". National Science Review. doi:10.1093/nsr/nwaa036. ISSN 2095-5138.
- ↑ 4.0 4.1 4.2 Tavazzi, Guido; Pellegrini, Carlo; Maurelli, Marco; Belliato, Mirko; Sciutti, Fabio; Bottazzi, Andrea; Sepe, Paola Alessandra; Resasco, Tullia; Camporotondo, Rita; Bruno, Raffaele; Baldanti, Fausto; Paolucci, Stefania; Pelenghi, Stefano; Iotti, Giorgio Antonio; Mojoli, Francesco; Arbustini, Eloisa (2020). "Myocardial localization of coronavirus in COVID‐19 cardiogenic shock". European Journal of Heart Failure. 22 (5): 911–915. doi:10.1002/ejhf.1828. ISSN 1388-9842.
- ↑ Siddiqi, Hasan K.; Mehra, Mandeep R. (2020). "COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal". The Journal of Heart and Lung Transplantation. 39 (5): 405–407. doi:10.1016/j.healun.2020.03.012. ISSN 1053-2498.
- ↑ Ye, Qing; Wang, Bili; Mao, Jianhua (2020). "The pathogenesis and treatment of the `Cytokine Storm' in COVID-19". Journal of Infection. 80 (6): 607–613. doi:10.1016/j.jinf.2020.03.037. ISSN 0163-4453.
- ↑ Mahajan, Kunal; Chandra, K.Sarat (2020). "Cardiovascular comorbidities and complications associated with coronavirus disease 2019". Medical Journal Armed Forces India. doi:10.1016/j.mjafi.2020.05.004. ISSN 0377-1237.
- ↑ Belhadjer, Zahra; Méot, Mathilde; Bajolle, Fanny; Khraiche, Diala; Legendre, Antoine; Abakka, Samya; Auriau, Johanne; Grimaud, Marion; Oualha, Mehdi; Beghetti, Maurice; Wacker, Julie; Ovaert, Caroline; Hascoet, Sebastien; Selegny, Maëlle; Malekzadeh-Milani, Sophie; Maltret, Alice; Bosser, Gilles; Giroux, Nathan; Bonnemains, Laurent; Bordet, Jeanne; Di Filippo, Sylvie; Mauran, Pierre; Falcon-Eicher, Sylvie; Thambo, Jean-Benoît; Lefort, Bruno; Moceri, Pamela; Houyel, Lucile; Renolleau, Sylvain; Bonnet, Damien (2020). "Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic". Circulation. doi:10.1161/CIRCULATIONAHA.120.048360. ISSN 0009-7322.
- ↑ Boukhris, Marouane; Hillani, Ali; Moroni, Francesco; Annabi, Mohamed Salah; Addad, Faouzi; Ribeiro, Marcelo Harada; Mansour, Samer; Zhao, Xiaohui; Ybarra, Luiz Fernando; Abbate, Antonio; Vilca, Luz Maria; Azzalini, Lorenzo (2020). "Cardiovascular Implications of the COVID-19 Pandemic: A Global Perspective". Canadian Journal of Cardiology. doi:10.1016/j.cjca.2020.05.018. ISSN 0828-282X.
- ↑ Rajagopal, Keshava; Keller, Steven P.; Akkanti, Bindu; Bime, Christian; Loyalka, Pranav; Cheema, Faisal H.; Zwischenberger, Joseph B.; El Banayosy, Aly; Pappalardo, Federico; Slaughter, Mark S.; Slepian, Marvin J. (2020). "Advanced Pulmonary and Cardiac Support of COVID-19 Patients". Circulation: Heart Failure. 13 (5). doi:10.1161/CIRCHEARTFAILURE.120.007175. ISSN 1941-3289.
- ↑ Jameson, J (2018). Harrison's principles of internal medicine. New York: McGraw-Hill Education. ISBN 1259644030.
- ↑ Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M; et al. (2020). "Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State". JAMA. doi:10.1001/jama.2020.4326. PMC 7082763 Check
|pmc=
value (help). PMID 32191259 Check|pmid=
value (help). - ↑ 13.0 13.1 Sánchez-Recalde, Ángel; Solano-López, Jorge; Miguelena-Hycka, Javier; Martín-Pinacho, Jesús Javier; Sanmartín, Marcelo; Zamorano, José L. (2020). "COVID-19 and cardiogenic shock. Different cardiovascular presentations with high mortality". Revista Española de Cardiología (English Edition). doi:10.1016/j.rec.2020.04.012. ISSN 1885-5857.
- ↑ 14.0 14.1 Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H; et al. (2020). "Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study". Lancet Respir Med. 8 (5): 475–481. doi:10.1016/S2213-2600(20)30079-5. PMC 7102538 Check
|pmc=
value (help). PMID 32105632 Check|pmid=
value (help). - ↑ 15.0 15.1 Dhakal, Bishnu P.; Sweitzer, Nancy K.; Indik, Julia H.; Acharya, Deepak; William, Preethi (2020). "SARS-CoV-2 Infection and Cardiovascular Disease: COVID-19 Heart". Heart, Lung and Circulation. doi:10.1016/j.hlc.2020.05.101. ISSN 1443-9506.
- ↑ Tse, FirstName (2011). Oxford Desk Reference : Cardiology. Oxford: OUP Oxford. ISBN 978-0-19-956809-3.
- ↑ 17.0 17.1 Lal, Sean; Hayward, Christopher S.; De Pasquale, Carmine; Kaye, David; Javorsky, George; Bergin, Peter; Atherton, John J.; Ilton, Marcus K.; Weintraub, Robert G.; Nair, Priya; Rudas, Mate; Dembo, Lawrence; Doughty, Robert N.; Kumarasinghe, Gayathri; Juergens, Craig; Bannon, Paul G.; Bart, Nicole K.; Chow, Clara K.; Lattimore, Jo-Dee; Kritharides, Leonard; Totaro, Richard; Macdonald, Peter S. (2020). "COVID-19 and Acute Heart Failure: Screening the Critically Ill – A Position Statement of the Cardiac Society of Australia and New Zealand (CSANZ)". Heart, Lung and Circulation. doi:10.1016/j.hlc.2020.04.005. ISSN 1443-9506.
- ↑ Aboughdir, Maryam; Kirwin, Thomas; Abdul Khader, Ashiq; Wang, Brian (2020). "Prognostic Value of Cardiovascular Biomarkers in COVID-19: A Review". Viruses. 12 (5): 527. doi:10.3390/v12050527. ISSN 1999-4915.
- ↑ Tse, FirstName (2011). Oxford Desk Reference : Cardiology. Oxford: OUP Oxford. ISBN 978-0-19-956809-3.
- ↑ 20.0 20.1 Driggin, Elissa; Madhavan, Mahesh V.; Bikdeli, Behnood; Chuich, Taylor; Laracy, Justin; Biondi-Zoccai, Giuseppe; Brown, Tyler S.; Der Nigoghossian, Caroline; Zidar, David A.; Haythe, Jennifer; Brodie, Daniel; Beckman, Joshua A.; Kirtane, Ajay J.; Stone, Gregg W.; Krumholz, Harlan M.; Parikh, Sahil A. (2020). "Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic". Journal of the American College of Cardiology. 75 (18): 2352–2371. doi:10.1016/j.jacc.2020.03.031. ISSN 0735-1097.
- ↑ 21.0 21.1 Dhakal BP, Sweitzer NK, Indik JH, Acharya D, William P (2020). "SARS-CoV-2 Infection and Cardiovascular Disease: COVID-19 Heart". Heart Lung Circ. doi:10.1016/j.hlc.2020.05.101. PMC 7274628 Check
|pmc=
value (help). PMID 32601020 Check|pmid=
value (help). - ↑ MacLaren, Graeme; Fisher, Dale; Brodie, Daniel (2020). "Preparing for the Most Critically Ill Patients With COVID-19". JAMA. 323 (13): 1245. doi:10.1001/jama.2020.2342. ISSN 0098-7484.